NanoString Technologies

NanoString Technologies, Inc

Type	Public
Traded as	Nasdaq: NSTG Russell 2000 Component
Industry	Biotechnology
Founded	2003[1]
Founders	Krassen Dimitrov, Amber Ratcliffe, Dwayne Dunaway
Headquarters	South Lake Union, Seattle, Washington , United States
Key people	Brad Gray, CEO
Products	nCounter® Analysis System, GeoMx® Digital Spatial Profiler
Brands	nCounter®, GeoMx® DSP
Revenue	$147.6 million[1] (2014)
Total equity	$204 million[1] (2015)
Number of employees	270[1] (2015)
Website	www.nanostring.com

This article contains content that is written like an advertisement. Please help by removing promotional content and inappropriate external links, and by adding encyclopedic content written from a neutral point of view. (February 2021) (Learn how and when to remove this template message)

NanoString Technologies, Inc. (NASDAQ: NSTG) is a publicly held biotech company that specializes in development of translational research tools.^[1] The company was founded by Krassen Dimitrov, Amber Ratcliffe, and Dwayne Dunaway in 2003,^[2][3] and is based in Seattle, Washington.^[4]

Key Technology & Products[]

NanoString's nCounter is a variation on the DNA microarray and was invented and patented by Krassen Dimitrov and Dwayne Dunaway.^{[citation needed]} It uses molecular "barcodes" and microscopic imaging to detect and count up to several hundred transcripts in hybridization reaction.^[5]

More recently, nanoString introduced the GeoMx DSP (Digital Spatial Profiler) to help provide single cell resolution in a spatial context.

History[]

The original patent that is the basis for the nCounter Analysis System was invented and licensed from The Institute for Systems Biology. The business plan was written by Amber Ratcliffe and Aaron Coe and won seed funding in multiple business plan competitions.^[6] NanoString was spun out of The Institute for Systems Biology and founded as a separate company in 2003 by Krassen Dimitrov, Amber Ratcliffe and Dwayne Dunaway.^{[citation needed]}

In 2004, NanoString raised its first significant funding in a $4.3M series A financing.^{[citation needed]} They have since raised several more rounds of financing to expand into the development of molecular diagnostics. As of 2011, NanoString Technologies had raised nearly $70M with their series D.^{[7][citation needed]}

In 2009, Perry Fell who had been CEO since 2004, left the company abruptly and with no official explanation.^[8] Between 2009 and 2010 the company operated with an acting CEO, Wayne Burns.^[9] Brad Gray, a former Genzyme executive, was hired as president and CEO in 2010.^[9]

As of June 2010, the company was not yet profitable.^[9] In an interview, Gray suggested that NanoString would begin to develop clinical diagnostics.^[9] As of July, 2012, NanoString began indicating a move towards becoming a public company by hiring several senior staff with public company experience.^[10]

In 2013, the company's IPO raised funding that was used to expand NanoString sales and marketing.^[1]

References[]